A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and safety of 2 oral doses of CP-690, 550 and 1 subcuaneous dose of etanercept in subjects with moderate ot severe chronic plaque psoriasis